
Pyxis Oncology (PYXS) Stock Forecast & Price Target
Pyxis Oncology (PYXS) Analyst Ratings
Bulls say
Pyxis Oncology Inc has seen an increase in its probability of success for regulatory approval of its product candidate MICVO, rising from 15% to 25%, which signals a more optimistic outlook for the company's future. The newly projected overall response rate assumptions for MICVO suggest significant potential efficacy, particularly in combination with Keytruda, indicating a strong foundation for future success in clinical trials. Additionally, expectations of a positive trial readout, coupled with potential capital raises planned for 2026 to 2028, enhance the company’s strategic positioning and long-term investment prospects.
Bears say
Pyxis Oncology faces a negative outlook primarily due to its inability to defend its portfolio, which could significantly diminish its market potential and limit growth prospects. Additionally, the company's challenges in accessing capital could jeopardize critical business functions, delaying profitability and cash flow generation. Furthermore, unfavorable clinical trial data, reliance on third-party contract manufacturing, and intense competition in the oncology sector further compound the risks associated with its development of next-generation therapeutics.
This aggregate rating is based on analysts' research of Pyxis Oncology and is not a guaranteed prediction by Public.com or investment advice.
Pyxis Oncology (PYXS) Analyst Forecast & Price Prediction
Start investing in Pyxis Oncology (PYXS)
Order type
Buy in
Order amount
Est. shares
0 shares